

DAFTAR PUSTAKA

1. Listiana A, Adistikah A, Maulidiah I, editors. Kementerian Kesehatan Republik Indonesia. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Juli 2020. Vol. 5. Jakarta: Kementerian Kesehatan RI; 2020. 1–214 p)
2. World Health Organization. COVID-19 Clinical Management 4th version. World Health Organization. Geneva; 2021.
3. Kementerian Kesehatan Republik Indonesia. Situasi Terkini Perkembangan COVID-19. Jakarta; 2021
4. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584:430–6.
5. Albashir AAD. The potential impacts of obesity on COVID-19. *Clin Med (Lond)*. 2020;20(4):109-13.
6. Rao X, Wu C, Wang S. The importance of overweight in COVID-19: A retrospective analysis in a single center of Wuhan, China. *Medicine (Baltimore)*. 2020;99(43):1-11
7. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. *J Clin Endocrinol Metab*. 2020;105(8):346-74
8. Yu W, Rohli KE, Yang S, Jia P. Impact of obesity on COVID-19 patients. *J Diabetes Complications*. 2021;35(3):1-13
9. Moriconi D, Masi S, Rebelos E, Virdis A, Manca ML, De Marco S, et al. Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding. *Obes Res Clin Pract* 2020;14:205-9.
10. Dreher M, Kersten A, Bickenbach J, Balfanz P, Hartmann B, Cornelissen C, et al. The characteristics of 50 hospitalized COVID-19 patients with and without ARDS. *Dtsch Arztebl Int* 2020;117:271-8
11. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. *JAMA Intern Med* 2020;180:1-12.

12. Crusio WE, Dong H, Radeke HH, Rezaei N, Xiao J. *Advances in Experimental Medicine and Biology*. Tehran: Springer; 2020. p. 61.
13. World Health Organization. COVID-19 Weekly Epidemiological Update Edition 54. World Health Organization. Geneva; 2021.
14. Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. *Trends in Immunology* 2020; 41: 1100–15.
15. Tangianu F, Para O, Capello F. *COVID-19 in Clinical Practice Lessons Learned and Future Perspectives*. 1st edition. Switzerland: Springer; 2021. p. 10-2.
16. Krishnan A, Hamilton JP, Alqahtani SA. COVID-19: An overview and a clinical update. *World Journal of Clinical Cases* 2021; 9: 8–23.
17. Harjatmo TP, Par'i HM, Wiyono S. *Buku Ajar Penilaian Status Gizi*. Jakarta: EGC; 2017. p. 212-24.
18. Lim JU, Lee JH, Kim JS. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. *Int J Chron Obstruct Pulmon Dis*. 2017; 12: 2465-75.
19. Kementerian Kesehatan Republik Indonesia. *Klasifikasi Obesitas setelah pengukuran IMT*. Jakarta: P2PTM; 7 November 2018 [diakses 20 Agustus 2021].
20. Dixon AE, Peters U. The effect of obesity on lung function. *Expert Rev Respir Med*. 2018; 12(9): 755-67.
21. Peters U, Suratt BT, Bates JHT, Dixon AE. Beyond BMI: Obesity and Lung Disease. *Chest*. 2018; 153(3): 702-9.
22. De Bandt JP, Monin C. Obesity, Nutrients and the Immune System in the Era of COVID-19. *Nutrients*. 2021; 13(610): 1-14.
23. De Frel DL, Atsma DE, Pijl H. The Impact of Obesity and Lifestyle on the Immune System and Susceptibility to Infections Such as COVID-19. *Front Nutr*. 2020;7(5):1-12.
24. Gleeson LE, Roche HM, Sheedy FJ. Obesity, COVID-19 and innate immunometabolism. *Br J Nutr*. 2021;125(6):628-32.
25. Mustafa MI, Abdelmoneim AH, Mahmoud EM, Makhawi AM. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment

by QTY Code-Designed Detergent-Free Chemokine Receptors. *Mediators Inflamm.* 2020;2020(8):1-7.

26. Mehanna O, Askary A el, Ali E. Impact of obesity and its associated comorbid conditions on COVID-19 presentation. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* 2021; 14: 409–15.
27. Khasawneh L, Al-Omar K, Adnan Tarifi A. The correlation between BMI and COVID-19 outcomes. *Systematic Reviews in Pharmacy* 2020; 11: 1236–9.
28. Demeulemeester F, de Punder K, van Heijningen M, van Doesburg F. Obesity as a Risk Factor for Severe COVID-19 and Complications: A Review. *Cells.* 2021; 10(933): 5-11.
29. Aghili SMM, Ebrahimpur M, Arjmand B. Obesity in COVID-19 era, implications for mechanisms, comorbidities, and prognosis: a review and meta-analysis. *Int J Obes (Lond).* 2021;45(5):998-1016.
30. Hamer M, Gale CR, Kivimäki M, Batty GD. Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom. *Proc Natl Acad Sci U S A.* 2020;117(35):21011-13.
31. Rossi AP, Gottin L, Donadello K. Obesity as a risk factor for unfavourable outcomes in critically ill patients affected by Covid 19. *Nutr Metab Cardiovasc Dis.* 2021;31(3):762-8.
32. Sjögren L, Stenberg E, Thuccani M. Impact of obesity on intensive care outcomes in patients with COVID-19 in Sweden-A cohort study. *PLoS One.* 2021;16(10): 1-7.
33. Popkin BM, Du S, Green WD. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. *Obesity Reviews.* 2021; 22(10): 1-17.
34. Ellulu MS, Patimah I, Khaza'ai H. Obesity & inflammation: The linking mechanism & the complications. *Archives of Medical Science* 2017; 13: 851–63.

35. McNeill JN, Lau ES, Paniagua SM. The role of obesity in inflammatory markers in COVID-19 patients. *Obesity Research and Clinical Practice* 2021; 15: 96–9.
36. Chiappetta S, Sharma AM, Bottino V. COVID-19 and the role of chronic inflammation in patients with obesity. *International Journal of Obesity* 2020; 44: 1790–2.
37. Helvaci N, Eyupoglu ND, Karabulut E, Yildiz BO. Prevalence of Obesity and Its Impact on Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis. *Front Endocrinol (Lausanne)*. 2021; 12(598249) : 1-13.
38. El Kassas GM, Shehata MA, el Wakeel MA. Role of procalcitonin as an inflammatory marker in a sample of egyptian children with simple obesity. *Open Access Macedonian Journal of Medical Sciences* 2018; 6: 1349–53.
39. Mesgari-Abbasi M, Mahmoudinezhad M, Farhangi MA. Soluble P-selectin, procalcitonin, transforming growth factor (TGF)- β and apo-proteins in association with the components of metabolic syndrome in obese individuals. *Clinical Nutrition ESPEN*. 2021; 41: 386–90.
40. Pasquarelli-do-Nascimento G, Braz-de-Melo HA, Faria SS, Santos IO, Kobinger GP, Magalhães KG. Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity. *Front Endocrinol (Lausanne)*. 2020; 11(530): 1-16.
41. Sahin S, Sezer H, Cicek E. The role of obesity in predicting the clinical outcomes of COVID-19. *Obesity Facts* 2021; 14: 481–9.
42. Foulkes AS, Selvaggi C, Shinnick D. Understanding the link between obesity and severe COVID-19 outcomes: Causal mediation by systemic inflammatory response. *J Clin Endocrinol Metab*. 2021;(20):10-39.
43. Lemyze M, Courageux N, Maladobry T. Implications of Obesity for the Management of Severe Coronavirus Disease 2019 Pneumonia. *Crit Care Med*. 2020;48(9):761-7.
44. Peres KC, Riera R, Martimbianco ALC, Ward LS, Cunha LL. Body Mass Index and Prognosis of COVID-19 Infection. A Systematic Review. *Front Endocrinol (Lausanne)*. 2020;11:562-9.

45. Recalde M, Pistillo A, Fernandez-Bertolin S. Body mass index and risk of COVID-19 diagnosis, hospitalisation, and death: a cohort study of 2.524.926 Catalans. *J Clin Endocrinol Metab.* 2021;106:(12):5030-42.
46. Thakur B, Dubey P, Benitez J. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. *Sci Rep.* 2021;11(1):1-14.
47. Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. *PLoS One* 2021; 16(10): 1-18.
48. Li X, Guan B, Su T. Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: A systematic review and meta-analysis. *Heart* 2020; 106: 1142–7.
49. Driggin E, Madhavan MV, Bikdeli B. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. *J Am Coll Cardiol.* 2020;75(18):2352-71.
50. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. *Lancet Infect Dis.* 2010;10(2):83-92.
51. Han Y, Zeng H, Jiang H. CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic. *Circulation* 2020; E810–E816.
52. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol.* 2020;5(7):811-8.
53. Shi S, Qin M, Shen B. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol* 2020;5(7):802-10.
54. Zuin M, Rigatelli G, Zuliani G, Rigatelli A, Mazza A, Roncon L. Arterial hypertension and risk of death in patients with COVID-19 infection: Systematic review and meta-analysis. *J Infect* 2020;81(1):84-6.

55. Huang S, Wang J, Liu F. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. *Hypertens Res* 2020;43(8):824-31.
56. Moftakhar L, Pirae E, Mohammadi Abnavi M, Moftakhar P, Azarbakhsh H, Valipour A. Epidemiological Features and Predictors of Mortality in Patients with COVID-19 with and without Underlying Hypertension. *Int J Hypertens* 2021;7427500:1-7.
57. Kumar A, Arora A, Sharma P. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews* 2020; 14: 535–45.
58. Angelidi AM, Belanger MJ, Mantzoros CS. Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next. *Metabolism*. 2020;107:1-6.
59. Wu Z hong, Tang Y, Cheng Q. Diabetes increases the mortality of patients with COVID-19: a meta-analysis. *Acta Diabetologica* 2021;58:139–44.
60. Lee SC, Son KJ, Han CH, Park SC, Jung JY. Impact of COPD on COVID-19 prognosis: A nationwide population-based study in South Korea. *Sci Rep*. 2021;11(1):1-8.
61. Lee SC, Son KJ, Han CH, Jung JY, Park SC. Impact of comorbid asthma on severity of coronavirus disease (COVID-19). *Sci Rep*. 2020;10(1):1-10.
62. Yang JM, Koh HY, Moon SY. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. *Journal of Allergy and Clinical Immunology* 2020; 146: 790–8.
63. Choi YJ, Park JY, Lee HS. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. *Eur Respir J*. 2021;57(3):1-11.
64. Gao Y, Liu M, Chen Y. Association between tuberculosis and COVID-19 severity and mortality: A rapid systematic review and meta-analysis. *Journal of Medical Virology* 2021; 93: 194–6.
65. Li X, Xu S, Yu M. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *Journal of Allergy and Clinical Immunology* 2020; 146: 110–8.

66. Singh J, Malik P, Patel N. Kidney disease and COVID-19 disease severity- systematic review and meta-analysis [published online ahead of print, 2021 Apr 23]. *Clin Exp Med.* 2021;1-11.
67. Shao M, Li X, Liu F, Tian T, Luo J, Yang Y. Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: A systematic review and meta-analysis of 40 studies and 24,527 patients. *Pharmacol Res.* 2020;161:1-13.
68. Cheng Y, Luo R, Wang K. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney International* 2020; 97: 829–38.
69. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. *Journal of Thrombosis and Haemostasis* 2020;18:786-7.
70. Florez-Perdomo WA, Serrato-Vargas SA, Bosque-Varela P. Relationship between the history of cerebrovascular disease and mortality in COVID-19 patients: A systematic review and meta-analysis. *Clin Neurol Neurosurg.* 2020;197:1-5.
71. Aggarwal G, Lippi G, Michael Henry B. Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature. *International Journal of Stroke* 2020; 15: 385–9.
72. Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. *J Stroke Cerebrovasc Dis.* 2020;29(8):1-9.
73. Lin L, Lu L, Cao W. Hypothesis for potential pathogenesis of SARS-CoV-2 infection—a review of immune changes in patients with viral pneumonia. *Emerging Microbes and Infections* 2020; 9: 727–32.
74. Yang R, Gui X, Zhang Y. The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients. *Expert Review of Respiratory Medicine* 2020; 14: 835–8.
75. Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liverdisease in patients with COVID-19 and their clinical outcomes: a systematicreview and meta-analysis. *Hepatology International* 2020; 14: 612–20.

76. Sharma A, Jaiswal P, Kerakhan Y. Liver disease and outcomes among COVID-19 hospitalized patients - A systematic review and meta-analysis. *Ann Hepatol.* 2021;21:1-24.
77. Chai X, Hu L, Zhang Y. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. *bioRxiv* 2020;2:1-13.
78. Shields AM, Burns SO, Savic S. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. *Journal of Allergy and Clinical Immunology* 2021; 147: 870-5.
79. Docherty AB, Harrison EM, Green CA. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020;369:1-12.
80. Kates OS, Haydel BM, Florman SS. Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. *Clin Infect Dis.* 2021;73(11):4090-9.
81. Zhang H, Han H, He T. Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. *Journal of the National Cancer Institute* 2021; 113: 371–80.
82. Vijenthira A, Gong IY, Fox TA. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. *Blood.* 2020;136(25):2881-92.
83. Yang L, Chai P, Yu J. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. *Cancer Biology and Medicine* 2021; 18: 298–307.
84. Surendra H, Elyazar IR, Djaafara BA. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. *Lancet Reg Health West Pac* 2021; 9(100108): 1-9.
85. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, et al. Pedoman Tatalaksana Covid-19 Edisi 3. Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi. 2020; 6(3): 88–9.

86. Dana R, Bannay A, Bourst P. Obesity and mortality in critically ill COVID-19 patients with respiratory failure. *International journal of obesity* 2021; 45: 2028–37.
87. Huang Y, Lu Y, Huang YM. Obesity in patients with COVID-19: a systematic review and meta-analysis. *Metabolism*. 2020;113:2-13.
88. Pettit NN, MacKenzie EL, Ridgway JP. Obesity is Associated with Increased Risk for Mortality Among Hospitalized Patients with COVID-19. *Obesity* 2020; 28:1806–10.
89. Shahid Z, Kalayanamitra R, McClafferty B. COVID-19 and Older Adults: What We Know. *Journal of the American Geriatrics Society* 2020; 68: 926–9.
90. Callender LA, Curran M, Bates SM. The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. *Frontiers in Immunology* 2020; 11: 1–16.
91. Prasad DS, Kabir Z, Revathi Devi K. Gender differences in central obesity: Implications for cardiometabolic health in South Asians. *Indian Heart Journal* 2020; 72: 202–4.
92. Aslan G, Karadag Arli S, Berivan Bakan A. Obesity and risk factors in women aged between 18 and 64. *International Journal of Caring Science* 2019; 12: 218–223.
93. Verma AA, Hora T, Jung HY. Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area. *CMAJ*. 2021;193(12):410-8.
94. Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women?. *SN Compr Clin Med*. 2020;2(7):874-6.
95. Cai Z, Yang Y, Zhang J. Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis. *BMC Public Health*. 2021;21(1):1505:1-7.
96. Ferreira MER, de Andrade AVS, Queiroz AAF. Covid-19 and obesity: A systematic review and meta-analysis on the pre-existing clinical conditions, covid-19 symptoms, laboratory findings and clinical outcomes. *EXCLI Journal* 2021; 20: 1610-4.

97. Caci G, Albini A, Malerba M. Covid-19 and obesity: Dangerous liaisons. *Journal of Clinical Medicine* 2020; 9: 1–12.
98. Parmar MY. Obesity and Type 2 diabetes mellitus. *Integr Obesity Diabetes*. 2018; 4(4): 1-2.
99. Al Heialy S, Hachim MY, Hachim IY. Combination of obesity and co-morbidities leads to unfavorable outcomes in COVID-19 patients. *Saudi Journal of Biological Sciences* 2021; 28: 1445–50.
100. Osibogun A, Balogun M, Abayomi A. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. *PLoS One*. 2021;16(3):e0248281. 1-12.
101. Poly TN, Islam MM, Yang HC. Obesity and Mortality Among Patients Diagnosed With COVID-19: A Systematic Review and Meta-Analysis. *Front Med (Lausanne)*. 2021;8:1-11.
102. Tartof SY, Qian L, Hong V. Obesity and mortality among patients diagnosed with COVID-19: Results from an integrated health care organization. *Annals of Internal Medicine* 2020; 173: 773–81.
103. Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. *Gland Surg*. 2020;9(1):80-93.
104. Kotsis V, Martinez F, Trakatelli C, Redon J. Impact of Obesity in Kidney Diseases. *Nutrients*. 2021;13(12):2-16.
105. Pugliese, G., Liccardi, A., Graziadio, C. et al. Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition. *Int J Obes*. 2022; 46: 449–65.
106. Harris R, Card TR, Delahooke T, Aithal GP, Guha IN. Obesity Is the Most Common Risk Factor for Chronic Liver Disease: Results From a Risk Stratification Pathway Using Transient Elastography. *Am J Gastroenterol*. 2019;114(11):1744-52.
107. Ni YN, Yu H, Xu H. High Visceral Adipose Tissue to Subcutaneous Adipose Tissue Ratio as a Predictor of Mortality in Acute Respiratory Distress Syndrome. *American Journal of the Medical Sciences* 2019; 357: 213–22.

108. Bennasrallah C, Zemni I, Dhouib W. Factors associated with a prolonged negative conversion of viral RNA in patients with COVID-19. *International Journal of Infectious Diseases* 2021; 105: 463–9.
109. Mo P, Deng L, Liu X. Risk factors for delayed negative conversion of SARS-CoV-2 in patients with COVID-19 pneumonia: a retrospective cohort study. *Epidemiol Infect.* 2020;148:1-7.
110. Zhang X, Lin B, Yang G. Delayed SARS-CoV-2 clearance in patients with Obesity. *Infection and Drug Resistance* 2021; 14: 2823-7.
111. Pouwels S, Ramnarain D, Aupers E, Rutjes-Weurding L, van Oers J. Obesity May Not Be Associated with 28-Day Mortality, Duration of Invasive Mechanical Ventilation and Length of Intensive Care Unit and Hospital Stay in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus-2: A Retrospective Cohort Study. *Medicina(Kaunas).* 2021;57(7):674:1-9.
112. Suresh S, Siddiqui M, Abu Ghanimeh M. Association of obesity with illness severity in hospitalized patients with COVID-19: A retrospective cohort study. *Obesity Research and Clinical Practice* 2021; 15: 172–6.
113. Plataki M, Pan D, Goyal P. Association of body mass index with morbidity in patients hospitalised with COVID-19. *BMJ Open Respir Res.* 2021;8(1):1-11.

